Chemistry:Estradiol acetylsalicylate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Estradiol 3-acetylsalicylate; Acetylsalicylate estradiol |
| Routes of administration | By mouth |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H30O5 |
| Molar mass | 434.532 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estradiol acetylsalicylate, or estradiol 3-acetylsalicylate, is a synthetic estrogen and estrogen ester – specifically, the C3 acetylsalicylic acid (aspirin) ester of estradiol – which was described in the late 1980s and was never marketed.[1][2][3][4][5] In dogs, the oral bioavailability of estradiol acetylsalicylate was found to be 17-fold higher than that of unmodified estradiol.[1][4] However, a subsequent study found that the oral bioavailability of estradiol and estradiol acetylsalicylate did not differ significantly in rats (4.3% and 4.2%, respectively), suggestive of a major species difference.[2][4][6]
See also
References
- ↑ 1.0 1.1 "Prodrugs for improved oral beta-estradiol bioavailability". Pharmaceutical Research 5 (1): 44–47. January 1988. doi:10.1023/A:1015863412137. PMID 3244608.
- ↑ 2.0 2.1 "Oral bioavailability of 17β-estradiol and various ester prodrugs in the rat". International Journal of Pharmaceutics 76 (1–2): 177–182. 1991. doi:10.1016/0378-5173(91)90356-S. ISSN 0378-5173.
- ↑ "Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens". Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. 135 / 2. Springer Science & Business Media. 6 December 2012. pp. 263–. doi:10.1007/978-3-642-60107-1_15. ISBN 978-3-642-60107-1. https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA263.
- ↑ 4.0 4.1 4.2 "Prodrugs to Reduce Presystemic Metabolism". Prodrugs: Challenges and Rewards. Biotechnology: Pharmaceutical Aspects. Springer Science & Business Media. 26 August 2007. pp. 347–. doi:10.1007/978-0-387-49785-3_8. ISBN 978-0-387-49785-3. https://books.google.com/books?id=Ld4scqFQmgYC&pg=PA347.
- ↑ "Reducing Presystemic Drug Metabolism". Prodrugs and Targeted Delivery: Towards Better ADME Properties. John Wiley & Sons. 11 January 2011. pp. 218–. ISBN 978-3-527-63318-0. https://books.google.com/books?id=jYI5jtMA2qgC&pg=PA218.
- ↑ "Phenyl carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism". International Journal of Pharmaceutics 81 (2–3): 253–261. 1992. doi:10.1016/0378-5173(92)90017-V. ISSN 0378-5173.
 |  |
